FOLH1 and neoplasm: In summary, we have generated and tested in vivo a low-molecular-weight, PSMA-targeted prodrug that demonstrated tumor penetration and specificity sufficient to provide survival differences between PSMA + tumor-bearing animals and animals bearing isogenic tumors devoid of PSMA, including in a metastatic model.